Compare JD.Com Inc (JD) vs McKesson Corporation (MCK) Price & Performance

JD.com trades at $27.17, up 0.5% on the day, with strong analyst support (69.6% buy ratings) and a consensus price target of $35.86 suggesting 32% upside. Recent quarterly earnings have consistently beaten expectations, though revenue growth has slowed to 0.3% year-over-year for 2026. The stock appears fundamentally undervalued with a P/E of 17.9 and P/S of 0.2, while technical indicators show a mixed but slightly bullish bias with key support at $27.

JD offers significant valuation upside potential given its low multiples and strong cash position, but faces headwinds from slowing revenue growth and regulatory scrutiny of its European expansion. The company's robust balance sheet with $234 billion cash provides stability, though competitive pressures in Chinese e-commerce and macroeconomic concerns remain key risks for investors.

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.